Drug Search Results
More Filters [+]

APD-916

Alternative Names: apd-916, apd916, apd 916
Latest Update: 2010-11-02
Latest Update Note: Clinical Trial Update

Product Description

a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy

Mechanisms of Action: H3 Inverse Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for APD-916

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Cataplexy|Narcolepsy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

APD916-001

P1

Completed

Narcolepsy|Cataplexy

2010-04-01

Recent News Events

Date

Type

Title